BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Duchenne Muscular Dystrophy readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Duchenne Muscular Dys
 trophy\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06280209-10782@assetmemo.bio
DTSTAMP:20261121T005650Z
DTSTART;VALUE=DATE:20270414
DTEND;VALUE=DATE:20270415
SUMMARY:Nivudirsen (BMN 351): Phase 1/2 readout est. (NCT06280209)
DESCRIPTION:Nivudirsen (BMN 351)\, phase 1/2\, Duchenne Muscular Dystrophy.
 \nStudy: A Phase 1/2 Study to Assess the Safety\, Tolerability\, Pharmacok
 inetics\, and Pharmacodynamics of BMN 351 in Participants With Duchenne Mu
 scular Dystrophy\nEstimated primary completion: 14 April 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/nivudirsen-bmn-351#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT06280209
URL:https://assetmemo.bio/drug/nivudirsen-bmn-351#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06244082-11262@assetmemo.bio
DTSTAMP:20261121T005650Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Delpacibart zotadirsen: Phase 2 readout est. (NCT06244082)
DESCRIPTION:Delpacibart zotadirsen\, phase 2\, Duchenne Muscular Dystrophy.
 \nStudy: Ph2 Open-label Study of AOC 1044 in Duchenne Muscular Dystrophy P
 articipants With Mutations Amenable to Exon44 Skipping\nEstimated primary 
 completion: 30 April 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/delpacibart-zotadirsen#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT06244082
URL:https://assetmemo.bio/drug/delpacibart-zotadirsen#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05933057-3348@assetmemo.bio
DTSTAMP:20261121T005650Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Givinostat: Phase 3 readout est. (NCT05933057)
DESCRIPTION:Givinostat\, phase 3\, Duchenne Muscular Dystrophy.\nStudy: Eff
 icacy\, Safety and Tolerability of Givinostat in Non-ambulant Patients Wit
 h Duchenne Muscular Dystrophy\nEstimated primary completion: February 2028
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/givinostat#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT05933057
URL:https://assetmemo.bio/drug/givinostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07209332-10847@assetmemo.bio
DTSTAMP:20261121T005650Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Bampidirsen: Phase 2 readout est. (NCT07209332)
DESCRIPTION:Bampidirsen\, phase 2\, Duchenne Muscular Dystrophy.\nStudy: Op
 en-Label Extension Study of WVE-N531 in Patients With Duchenne Muscular Dy
 strophy\nEstimated primary completion: March 2029. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/bampidirsen#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07209332
URL:https://assetmemo.bio/drug/bampidirsen#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06769633-3348@assetmemo.bio
DTSTAMP:20261121T005650Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Givinostat: Phase 2 readout est. (NCT06769633)
DESCRIPTION:Givinostat\, phase 2\, Duchenne Muscular Dystrophy.\nStudy: Pha
 rmacokinetics and Safety of Givinostat in DMD Patients Ages From at Least 
 2 Years to Less Then 6 Years Old\nEstimated primary completion: December 2
 029. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/givinostat#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT06769633
URL:https://assetmemo.bio/drug/givinostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03373968-3348@assetmemo.bio
DTSTAMP:20261121T005650Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Givinostat: Phase 2/3 readout est. (NCT03373968)
DESCRIPTION:Givinostat\, phase 2/3\, Duchenne Muscular Dystrophy.\nStudy: G
 ivinostat in Duchenne's Muscular Dystrophy Long-term Safety and Tolerabili
 ty Study\nEstimated primary completion: December 2029. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/givinostat#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT03373968
URL:https://assetmemo.bio/drug/givinostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07573631-10782@assetmemo.bio
DTSTAMP:20261121T005650Z
DTSTART;VALUE=DATE:20311231
DTEND;VALUE=DATE:20320101
SUMMARY:Nivudirsen (BMN 351): Phase 2 readout est. (NCT07573631)
DESCRIPTION:Nivudirsen (BMN 351)\, phase 2\, Duchenne Muscular Dystrophy.\n
 Study: An Open-Label Extension Study to Evaluate the Long-term Safety and 
 Efficacy of BMN 351 in Participants With Duchenne Muscular Dystrophy\nEsti
 mated primary completion: December 2031. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/nivudirsen-bmn-351#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07573631
URL:https://assetmemo.bio/drug/nivudirsen-bmn-351#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
